A multi-center study comparing leadless pacemaker vs. standard pacemaker in patients with indication to ablate and pace for atrial fibrillation (LEAD-AP)
I Overeinder, L Pannone, W Zaher, G Mugnai, G Arabia, D G Della Rocca, G Bala, A Almorad, E Stroker, J Sieira, A Sarkozy, G B Chierchia, A Curnis, S Boveda, C De AsmundisAbstract
Background and aims
In patients with symptomatic permanent atrial fibrillation (AF) who are not candidates for rhythm control, atrioventricular node (AVN) ablation followed by ventricular pacing "ablate-and-pace" offers reliable rate control and symptom relief. Conventional transvenous systems are effective but associated with lead- and pocket-related complications. Leadless pacemakers represent a promising alternative, yet comparative data in this setting remain scarce. The aim is to compare clinical outcomes of leadless versus transvenous single-chamber pacemakers in patients undergoing AVN ablation for permanent AF.
Methods
We conducted a retrospective, multicenter study (LEAD-AP) of 168 consecutive patients undergoing ablate-and-pace between 2017 and 2024 across four European centers. Patients received either a leadless pacemaker (n=56) or a conventional transvenous VVI pacemaker (n=112). The primary efficacy endpoint was the composite of all-cause mortality, cardiovascular mortality, AF-related hospitalizations, unplanned visits and device-related hospitalizations or reinterventions. The secondary efficacy endpoint was device-related hospitalizations or reinterventions. The primary safety endpoint was acute complications within 30 days.
Results
Patients in the leadless group more frequently underwent a single-step ablate-and-pace strategy (96.4% vs 10.9%, p<0.001), resulting in shorter hospitalization (1.1 days ± 3.1 vs 5.7 days ± 2.2, p=0.008). At 24 months of follow-up, there was no statistically significant difference between patients with leadless pacemaker vs standard single-chamber VVI pacemaker in the event-free survival for the primary clinical efficacy endpoint (82.1 % vs 80.4 % Log-Rank p = 0.29), Figure 1 and 2.
Conclusions
Leadless pacemakers provide comparable safety and efficacy to transvenous systems in ablate-and-pace patients, while enabling shorter hospitalization through a streamlined single-step approach.Figure 1Figure 2